Healthequity (NASDAQ:HQY) had its price target increased by Robert W. Baird from $48.00 to $49.00 in a research report sent to investors on Wednesday morning. Robert W. Baird currently has a neutral rating on the stock.

Several other research firms have also issued reports on HQY. BidaskClub lowered shares of Healthequity from a hold rating to a sell rating in a research note on Thursday, December 7th. JPMorgan Chase & Co. reduced their price objective on shares of Healthequity from $52.00 to $51.00 and set an overweight rating for the company in a research note on Wednesday, January 24th. Zacks Investment Research lowered shares of Healthequity from a buy rating to a hold rating in a research note on Wednesday, November 15th. Chardan Capital lifted their price objective on shares of Healthequity from $58.00 to $62.00 and gave the company a buy rating in a research note on Wednesday, December 6th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $56.00 price objective on shares of Healthequity in a research note on Tuesday, December 5th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $56.67.

Shares of Healthequity (NASDAQ HQY) opened at $51.29 on Wednesday. The stock has a market cap of $3,111.92, a price-to-earnings ratio of 73.27, a price-to-earnings-growth ratio of 1.90 and a beta of 1.70. Healthequity has a 52 week low of $37.62 and a 52 week high of $55.31.

Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The company had revenue of $56.80 million during the quarter, compared to analyst estimates of $55.27 million. Healthequity had a net margin of 21.08% and a return on equity of 14.47%. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS. equities research analysts anticipate that Healthequity will post 0.73 earnings per share for the current year.

In related news, VP Darcy G. Mott sold 9,500 shares of Healthequity stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $47.91, for a total value of $455,145.00. Following the transaction, the vice president now owns 96,500 shares in the company, valued at approximately $4,623,315. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Delano Ladd sold 26,405 shares of Healthequity stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $43.32, for a total transaction of $1,143,864.60. Following the completion of the transaction, the executive vice president now owns 16,692 shares in the company, valued at approximately $723,097.44. The disclosure for this sale can be found here. Insiders sold a total of 371,426 shares of company stock worth $18,749,703 in the last quarter. Insiders own 29.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in HQY. Teachers Advisors LLC increased its holdings in shares of Healthequity by 12.6% during the 2nd quarter. Teachers Advisors LLC now owns 89,972 shares of the company’s stock worth $4,483,000 after purchasing an additional 10,079 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Healthequity by 5.0% during the 2nd quarter. New York State Common Retirement Fund now owns 159,277 shares of the company’s stock worth $7,937,000 after purchasing an additional 7,622 shares during the period. UBS Asset Management Americas Inc. increased its holdings in shares of Healthequity by 24.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 28,342 shares of the company’s stock worth $1,412,000 after purchasing an additional 5,544 shares during the period. Northern Trust Corp increased its holdings in shares of Healthequity by 14.1% during the 2nd quarter. Northern Trust Corp now owns 662,459 shares of the company’s stock worth $33,010,000 after purchasing an additional 81,665 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Healthequity by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,237,298 shares of the company’s stock worth $211,145,000 after purchasing an additional 122,061 shares during the period. Hedge funds and other institutional investors own 98.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/11/healthequity-hqy-given-new-49-00-price-target-at-robert-w-baird.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.